Navigation Links
Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
Date:8/17/2009

PALO ALTO, Calif., Aug. 17, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies with a focus on the NS4B Hepatitis C Virus (HCV) protein, announced today the appointment of Paul Truex to its Board of Directors.

Truex is the founder, President and CEO of Anthera Pharmaceuticals - a private pharmaceutical company focused on the development of anti-inflammatory products for life threatening cardiovascular and pulmonary diseases. Previously' he was Founder, President and CEO of Peninsula Pharmaceuticals where he negotiated both of Peninsula's anti-infective product agreements with Shionogi & Co.' Ltd. and Takeda Chemical Industries respectively. Peninsula was acquired by Johnson & Johnson in 2005 for $245 million. Previously, Mr. Truex held positions at Versicor (Vicuron), which was acquired by Pfizer for $1.9 billion, and at Eli Lilly. Mr. Truex obtained his M.B.A. in Marketing and Finance from Indiana University and a B.A. Degree in International Economics from the University of Waterloo.


"We are delighted to have Mr. Truex join Eiger's Board as an Independent Director," said David Cory, President and CEO of Eiger. "Paul will bring valuable experience to our corporate strategy and development as we advance both preclinical and clinical programs at Eiger."

"The combination of newly discovered HCV targets along with clinical and preclinical small molecule inhibitors already identified by Eiger make this a very exciting opportunity in the infectious disease space," said Paul Truex. "I'm looking forward to working with the Eiger board and management team to build a successful company."

Eiger BioPharmaceuticals recently announced the acquisition of exclusive license to novel HCV technology discovered in the labs of Stanford scientist and Eiger Founder Dr. Jeffrey Glenn, MD, PhD. This technology targets a specific region found in the HCV protein NS4B, which binds to HCV-RNA and is required for virus replication. Disrupting the function of this protein provides for a new method to treat HCV infection and can help combat drug resistance to HCV polymerase and protease inhibitors.

About Eiger BioPharmaceuticals, Inc. www.eigerbio.com

Eiger is focused on the discovery and development of new antiviral agents against novel targets for the treatment of hepatitis virus infection. Eiger's pipeline includes repurposed clinical stage therapeutic agents as well as NCEs from discovery that exhibit antiviral activity against Hepatitis C, Hepatitis D, and other viruses. Eiger investors include InterWest Partners www.interwest.com and Vivo Ventures www.vivoventures.com.

    Contact:
    1-650-320-9900
    info@eigerbio.com


'/>"/>
SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
2. Eiger BioPharmaceuticals Raises $7.1 Million A Round
3. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
8. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
9. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
10. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
11. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... , ... May 23, 2017 , ... Federal funding for ... as an enabler of life-saving medical and other vital technologies — deserves continued support, ... joined others in the scientific community today in responding to the President’s budget request ...
(Date:5/23/2017)... ... May 23, 2017 , ... Firmex today announced ... it easy for organizations to send and gather large files and confidential documents ... email file size limitations. , Using the same market-tested infrastructure as Firmex’s ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a ... anniversary, marking the occasion with a strong presence at Bio-IT World Conference & ... further extends an invitation to all attendees to view posters on the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Vortex Biosciences , ... “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology ” in Nature ... a collaboration with Dr. Dino Di Carlo and Dr. Matthew Rettig at the University ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
Breaking Biology News(10 mins):